Home / People / Tomáš Matĕjovský
Picture of Tomas Matejovsky

Tomáš Matĕjovský

Partner
Head of Commercial, Regulatory and Disputes

CMS Cameron McKenna Nabarro Olswang, advokáti, v.o.s.
Palladium, Na Poříčí 1079/3a
110 00 Prague 1
Czech Republic
Languages French, English, Czech
Commercial

Tomáš Matĕjovský is a partner and the Head of the Commercial, Regulatory and Disputes practice at CMS Prague.

He focuses on litigation and arbitration, compliance matters and white collar crime, and on commercial law, including employment, IP and competition. As part of his practice he represents clients in various types of litigations and arbitration proceedings at all levels, such as commercial, unfair competition and damage claim disputes before regional courts, Superior Courts, the Supreme Court, and the Constitutional Court and various arbitration bodies.

Tomáš also advises Czech and international companies on sector specific regulatory issues with particular focus on highly regulated industries such as the life sciences & healthcare, technology, media and communications sectors. His clients include major multinationals in these sectors.

In addition, he also supports clients on negotiating complex commercial agreements and advises on investments and investment incentives schemes in the CEE region.

more less

"Great knowledge of the legal system and excellent communication skills."

Chambers

Relevant experience

  • The Austrian and Slovak subsidiaries of Siemens in a major cross-border dispute over alleged pre-tender contractual liabilities linked to an important bidding process for railway security equipment.
  • Eastern Sugar in the Czech Republic in a EUR 41m claim against the Czech Republic.
  • Ministry of Agriculture concerning a wrongful allocation of its sugar quota and related significant ECHR claim against the Czech Republic.
  • Ministry of Finance of the Czech Republic in a significant arbitration valued at EUR 78.8m against a shareholder of a major Czech coal producer relating to a possible breach of a privatisation agreement by which the state's share was sold.
  • Global technology company and its insurers in a major multimillion euro damage claims regarding delivery and use of faulty electrical devices that caused a fire in one of the Prague’s main shopping gallery and office space in the centre of town, therefore representing a major health and safety risk.
  • A major telecommunications operator on the first stand-alone competition dispute with a competitor regarding margin squeeze in respect to providing of and access to broadband xDSL internet.
  • Diageo on the Czech regulation of food products and beverages, including labelling and packaging advice and distribution arrangements advice.
  • A leading biopharmaceutical company on all matters, including advising on employment law and lifesciences sector specific regulatory matters.
  • A global software company on several cyber-squatting and domain name matters and disputes as well as on trademark infringement issues, including oppositions against trademark applications.
  • A global IT company on several criminal investigations in relation to alleged bribery and corruption issues.
  • Worldwide medical devices producer on several compliance and anti-corruption investigations and relating matters. 
more less

Education

  • 1999 - International Law and State Administration Course, Ecole National d'Administration, Paris, France
  • 1998 - European Law, History and French Course, Universite de Perpignan, Perpignan, France
  • 1997 - Law Degree, Charles University, Prague
more less

Memberships

  • Member - Czech Bar Association
more less
Life Sciences & Healthcare

Tomáš Matĕjovský is a partner and the CEE Head of the Lifesciences & Healthcare sector group as well as Head of the Commercial, Regulatory and Disputes practice at CMS Prague.

He focuses on litigation and arbitration, compliance matters and white collar crime, and on commercial law, including employment, IP and competition. As part of his practice he represents clients in various types of litigations and arbitration proceedings at all levels, such as commercial, unfair competition and damage claim disputes before regional courts, Superior Courts, the Supreme Court, and the Constitutional Court and various arbitration bodies.

Tomáš advises various medical devices and pharmaceutical companies on various issues, including sector-specific regulatory matters, clinical trial problems and anti-corruption issues, as well as general commercial advice regarding company start-ups, distribution agreements and general day-to-day advice. He also advises on sector-specific regulatory issues in various due diligence processes.

In addition, he also supports clients on negotiating complex commercial agreements and advises on investments and investment incentives schemes in the CEE region.

more less

Relevant experience

  • A global pharmaceutical company | on regulatory data and patent protection against generics entry in the Czech Republic.
  • An original drug manufacturer | on regulatory data protection in the Czech Republic.
  • A French biopharmaceutical company | on its entry to the Czech market as well as on specific regulatory matters, including marketing authorisations relating to their pharmaceutical products, intellectual property rights with regards to trademarks, distribution in the Czech Republic, the establishment of distribution businesses in the Czech Republic and in Slovakia. This has included advising on structuring of the most efficient distribution models for both countries.
  • A global pharmaceutical corporation | on an internal investigation related to potential misconduct of their former Czech managing director, who was accused of unjustified preferential treatment, bossing some other employees and uneconomical conduct to the detriment of the company. We did a thorough audit of mailboxes of certain employees, conducted interviews with some of the employees and assisted the internal investigators of the corporation with some other tasks (review of accounting documents etc.).
  • A French biopharmaceutical company | on several proceedings against the Czech State Institute for Pharmaceuticals Control.
  • Various pharmaceutical companies | on various issues concerning public procurement issues in relation to public tenders, due diligence in public tender contracts, their participation in public tenders or their representation in administrative proceedings.
  • A pharmaceutical company | on distribution models (DTP), parallel trade issues as well as public procurement in the Czech Republic.
  • A global manufacturer of medical devices | providing ongoing legal advice to, pharmaceutical and consumer packaged goods on commercial law matters, including distribution systems and strategies, rebates as well as abuse of dominance.
  • A global medical products and technologies company | on pricing and reimbursement
  • A multinational biopharmaceutical company | in respect of its liability in the course of clinical trials of pharmaceuticals.
  • A multinational pharmaceutical company | in respect of a liability claim concerning defective medicinal product (vaccine).
more less

Education

  • 1999 - International Law and State Administration Course, Ecole National d'Administration, Paris, France
  • 1998 - European Law, History and French Course, Universite de Perpignan, Perpignan, France
  • 1997 - Law Degree, Charles University, Prague
more less

Memberships

  • Member - Czech Bar Association
more less

Feed

Show only
05 Dec 19
A leg­al roadmap for Can­nabis 2019
05 Dec 19
Czech gov­ern­ment gives green light for di­git­al tax on tech gi­ants
On 18 Novem­ber 2019, the Czech gov­ern­ment ap­proved a draft bill that in­tro­duces a 7% di­git­al tax on large tech­no­logy busi­nesses.  In in­tro­du­cing this bill, the Czech Re­pub­lic is fol­low­ing the ex­ample...
November 2019
CMS Pub­lic Pro­cure­ment Tool­box of Rem­ed­ies
Tool­box of rem­ed­ies in pub­lic award pro­ced­ures avail­able...
16 Oct 19
Czech La­bour Code amend­ment pro­posed for pro­cessing bio­met­ric data...
The Czech Data Pro­tec­tion Au­thor­ity has pro­posed an amend­ment to the Czech La­bour Code that would en­hance the abil­ity of em­ploy­ers to pro­cess the bio­met­ric per­son­al data of their staff. This pro­pos­al...
November 2019
E-pub­lic pro­cure­ment
E-pub­lic pro­cure­ment in a nut­shell
08 Oct 19
Czech lower house de­fies Sen­ate and re­af­firms sup­port for Amend­ment...
On 24 Septem­ber 2019, the lower house of the Czech par­lia­ment con­duc­ted a second vote on a draft Amend­ment to the Phar­ma­ceut­ic­als Act (No. 378/2007 Coll.), which was re­turned to the cham­ber after a vote...
CMS Ex­pert Guide to Dis­tri­bu­tion
02 Oct 19
Czech na­tion­al bank to toughen reg­u­la­tions on sale of add-on in­sur­ance...
The Czech Na­tion­al Bank (CNB) is con­sid­er­ing stricter reg­u­la­tions on the sale of add-on in­sur­ance products, fre­quently sold with elec­tron­ic devices, house­hold ap­pli­ances or hol­i­day pack­ages at the time...
CMS Ex­pert Guide to Pub­lic Pro­cure­ment
02 Aug 19
The Czech Re­pub­lic: Amend­ment to the Phar­ma­ceut­ic­als Act
On 25 Ju­ly 2019 the Czech Sen­ate dis­cussed a draft amend­ment to Act No. 378/2007 Coll., Phar­ma­ceut­ic­als Act, as amended (the “Amend­ment”) which was passed by the Cham­ber of Depu­ties at the end of...
01 Aug 19
Czech Re­pub­lic: New EU wide stand­ards to pro­tect whistle blowers
As we re­por­ted a few months ago (see Law-Now art­icle), a bill on the pro­tec­tion of whis­tleblowers is cur­rently go­ing through the le­gis­lat­ive pro­ced­ure after be­ing in­tro­duced by the Czech Gov­ern­ment earli­er...